Search

Your search keyword '"Winer, Eric"' showing total 714 results
Start Over Author "Winer, Eric" Publication Year Range Last 3 years
714 results on '"Winer, Eric"'

1. Subunit-specific analysis of cohesin-mutant myeloid malignancies reveals distinct ontogeny and outcomes

Author

Jann, Johann-Christoph, Hergott, Christopher B., Winkler, Marisa, Liu, Yiwen, Braun, Benjamin, Charles, Anne, Copson, Kevin M., Barua, Shougat, Meggendorfer, Manja, Nadarajah, Niroshan, Shimony, Shai, Winer, Eric S., Wadleigh, Martha, Stone, Richard M., DeAngelo, Daniel J., Garcia, Jacqueline S., Haferlach, Torsten, Lindsley, R. Coleman, Luskin, Marlise R., Stahl, Maximilian, and Tothova, Zuzana

Published
2024
Full Text
View/download PDF

4. HER2 heterogeneity and treatment response-associated profiles in HER2-positive breast cancer in the NCT02326974 clinical trial

Author

Li, Zheqi, Filho, Otto Metzger, Viale, Giuseppe, dell'Orto, Patrizia, Russo, Leila, Goyette, Marie-Anne, Kamat, Avni, Yardley, Denise A., Abramson, Vandana Gupta, Arteaga, Carlos L., Spring, Laura M., Chiotti, Kami, Halsey, Carol, Waks, Adrienne G., King, Tari A., Lester, Susan C., Bellon, Jennifer R., Winer, Eric P., Spellman, Paul T., Krop, Ian E., and Polyak, Kornelia

Subjects
Merck & Company Inc. -- Product development, Genentech Inc. -- Product development, Novartis AG -- Product development, Agilent Technologies Inc. -- Product development, AstraZeneca PLC -- Product development, Eli Lilly and Co. -- Product development, RNA sequencing, Biotechnology industry -- Product development, Pertuzumab, B cells, RNA, Clinical trials, Instrument industry -- Product development, Breast cancer, Pharmaceutical industry -- Product development, Health care industry
Abstract

BACKGROUND. HER2-targeting therapies have great efficacy in HER2-positive breast cancer, but resistance, in part due to HER2 heterogeneity (HET), is a significant clinical challenge. We previously described that in a phase II neoadjuvant trastuzumab emtansine (T-DM1) and pertuzumab (P) clinical trial in early-stage HER2-positive breast cancer, none of the patients with HER2-HET tumors had pathologic complete response (pCR). METHODS. To investigate cellular and molecular differences among tumors according to HER2 heterogeneity and pCR, we performed RNA sequencing and ERBB2 FISH of 285 pretreatment and posttreatment tumors from 129 patients in this T-DM1+P neoadjuvant trial. A subset of cases was also subject to NanoString spatial digital profiling. RESULTS. Pretreatment tumors from patients with pCR had the highest level of ERBB2 mRNA and ERBB signaling. HER2 heterogeneity was associated with no pCR, basal-like features, and low ERBB2 expression yet high ERBB signaling sustained by activation of downstream pathway components. Residual tumors showed decreased HER2 protein levels and ERBB2 copy number heterogeneity and increased PI3K pathway enrichment and luminal features. HET tumors showed minimal treatment-induced transcriptomic changes compared with non-HET tumors. Immune infiltration correlated with pCR and HER2-HET status. CONCLUSION. Resistance mechanisms in HET and non-HET tumors are distinct. HER2-targeting antibodies have limited efficacy in HET tumors. Our results support the stratification of patients based on HET status and the use of agents that target downstream components of the ERBB signaling pathway in patients with HET tumors. TRIAL REGISTRATION. ClinicalTrials.gov NCT02326974. FUNDING. This study was funded by Roche and the National Cancer Institute., Introduction Breast cancer is one of the most prevalent and life-threatening malignancies in women worldwide (1). Breast cancer is a heterogeneous disease clinically classified on the basis of the expression [...]

Published
2024
Full Text
View/download PDF

6. 6th and 7th International consensus guidelines for the management of advanced breast cancer (ABC guidelines 6 and 7)

Author

Cardoso, Fatima, Paluch-Shimon, Shani, Schumacher-Wulf, Eva, Matos, Leonor, Gelmon, Karen, Aapro, Matti S., Bajpai, Jyoti, Barrios, Carlos H., Bergh, Jonas, Bergsten-Nordström, Elizabeth, Biganzoli, Laura, Cardoso, Maria João, Carey, Lisa A., Chavez-MacGregor, Mariana, Chidebe, Runcie, Cortés, Javier, Curigliano, Giuseppe, Dent, Rebecca A., El Saghir, Nagi S., Eniu, Alexandru, Fallowfield, Lesley, Francis, Prudence A., Franco Millan, Sandra X., Gilchrist, Jenny, Gligorov, Joseph, Gradishar, William J., Haidinger, Renate, Harbeck, Nadia, Hu, Xichun, Kaur, Ranjit, Kiely, Belinda, Kim, Sung-Bae, Koppikar, Smruti, Kuper-Hommel, Marion J.J., Lecouvet, Frédéric E., Mason, Ginny, Mertz, Shirley A., Mueller, Volkmar, Myerson, Claire, Neciosup, Silvia, Offersen, Birgitte V., Ohno, Shinji, Pagani, Olivia, Partridge, Ann H., Penault-Llorca, Frédérique, Prat, Aleix, Rugo, Hope S., Senkus, Elzbieta, Sledge, George W., Swain, Sandra M., Thomssen, Christoph, Vorobiof, Daniel A., Vuylsteke, Peter, Wiseman, Theresa, Xu, Binghe, Costa, Alberto, Norton, Larry, and Winer, Eric P.

Published
2024
Full Text
View/download PDF

7. Pembrolizumab in brain metastases of diverse histologies: phase 2 trial results

Author

Brastianos, Priscilla K., Kim, Albert E., Giobbie-Hurder, Anita, Lee, Eudocia Q., Lin, Nancy U., Overmoyer, Beth, Wen, Patrick Y., Nayak, Lakshmi, Cohen, Justine V., Dietrich, Jorg, Eichler, April, Heist, Rebecca S., Krop, Ian, Lawrence, Donald, Ligibel, Jennifer, Tolaney, Sara, Mayer, Erica, Winer, Eric, Bent, Brittany, de Sauvage, Magali A., Ijad, Nazanin, Larson, Juliana M., Marion, Braxton, Nason, Sally, Murthy, Naina, Ratcliff, Sherry, Summers, Elizabeth J., Mahar, Maura, Shih, Helen A., Oh, Kevin, Cahill, Daniel P., Gerstner, Elizabeth R., and Sullivan, Ryan J.

Published
2023
Full Text
View/download PDF

8. Author Correction: Comprehensive genomic characterization of HER2-low and HER2-0 breast cancer

Author

Tarantino, Paolo, Gupta, Hersh, Hughes, Melissa E., Files, Janet, Strauss, Sarah, Kirkner, Gregory, Feeney, Anne-Marie, Li, Yvonne, Garrido-Castro, Ana C., Barroso-Sousa, Romualdo, Bychkovsky, Brittany L., DiLascio, Simona, Sholl, Lynette, MacConaill, Laura, Lindeman, Neal, Johnson, Bruce E., Meyerson, Matthew, Jeselsohn, Rinath, Qiu, Xintao, Li, Rong, Long, Henry, Winer, Eric P., Dillon, Deborah, Curigliano, Giuseppe, Cherniack, Andrew D., Tolaney, Sara M., and Lin, Nancy U.

Published
2023
Full Text
View/download PDF

10. Comprehensive genomic characterization of HER2-low and HER2-0 breast cancer

Author

Tarantino, Paolo, Gupta, Hersh, Hughes, Melissa E., Files, Janet, Strauss, Sarah, Kirkner, Gregory, Feeney, Anne-Marie, Li, Yvonne, Garrido-Castro, Ana C., Barroso-Sousa, Romualdo, Bychkovsky, Brittany L., DiLascio, Simona, Sholl, Lynette, MacConaill, Laura, Lindeman, Neal, Johnson, Bruce E., Meyerson, Matthew, Jeselsohn, Rinath, Qiu, Xintao, Li, Rong, Long, Henry, Winer, Eric P., Dillon, Deborah, Curigliano, Giuseppe, Cherniack, Andrew D., Tolaney, Sara M., and Lin, Nancy U.

Published
2023
Full Text
View/download PDF

11. Immunological and clinicopathological features predict HER2-positive breast cancer prognosis in the neoadjuvant NeoALTTO and CALGB 40601 randomized trials

Author

Rediti, Mattia, Fernandez-Martinez, Aranzazu, Venet, David, Rothé, Françoise, Hoadley, Katherine A., Parker, Joel S., Singh, Baljit, Campbell, Jordan D., Ballman, Karla V., Hillman, David W., Winer, Eric P., El-Abed, Sarra, Piccart, Martine, Di Cosimo, Serena, Symmans, William Fraser, Krop, Ian E., Salgado, Roberto, Loi, Sherene, Pusztai, Lajos, Perou, Charles M., Carey, Lisa A., and Sotiriou, Christos

Published
2023
Full Text
View/download PDF

13. Adjuvant Palbociclib for Early Breast Cancer: The PALLAS Trial Results (ABCSG-42/AFT-05/BIG-14-03).

Author

Steger, Guenther, Hernando Fernández de Aránguiz, Blanca, Haddad, Tufia, Perelló, Antonia, Bellet, Meritxell, Fohler, Hannes, Metzger Filho, Otto, Jallitsch-Halper, Anita, Solomon, Kadine, Schurmans, Céline, Theall, Kathy, Lu, Dongrui, Tenner, Kathleen, Fesl, Christian, DeMichele, Angela, Mayer, Erica, Gnant, Michael, Dueck, Amylou, Frantal, Sophie, Martin, Miguel, Burstein, Hal, Greil, Richard, Fox, Peter, Wolff, Antonio, Chan, Arlene, Winer, Eric, Pfeiler, Georg, Miller, Kathy, Colleoni, Marco, Suga, Jennifer, Rubovsky, Gabor, Bliss, Judith, Mayer, Ingrid, Singer, Christian, Nowecki, Zbigniew, Hahn, Olwen, Thomson, Jacqui, Wolmark, Norman, Amillano, Kepa, and Rugo, Hope

Subjects
Antineoplastic Agents, Hormonal, Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms, Chemotherapy, Adjuvant, Disease Progression, Disease-Free Survival, Female, Humans, Mastectomy, Middle Aged, Neoadjuvant Therapy, Neoplasm Staging, Piperazines, Progression-Free Survival, Prospective Studies, Protein Kinase Inhibitors, Pyridines, Time Factors
Abstract

PURPOSE: Palbociclib is a cyclin-dependent kinase 4 and 6 inhibitor approved for advanced breast cancer. In the adjuvant setting, the potential value of adding palbociclib to endocrine therapy for hormone receptor-positive breast cancer has not been confirmed. PATIENTS AND METHODS: In the prospective, randomized, phase III PALLAS trial, patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative early breast cancer were randomly assigned to receive 2 years of palbociclib (125 mg orally once daily, days 1-21 of a 28-day cycle) with adjuvant endocrine therapy or adjuvant endocrine therapy alone (for at least 5 years). The primary end point of the study was invasive disease-free survival (iDFS); secondary end points were invasive breast cancer-free survival, distant recurrence-free survival, locoregional cancer-free survival, and overall survival. RESULTS: Among 5,796 patients enrolled at 406 centers in 21 countries worldwide over 3 years, 5,761 were included in the intention-to-treat population. At the final protocol-defined analysis, at a median follow-up of 31 months, iDFS events occurred in 253 of 2,884 (8.8%) patients who received palbociclib plus endocrine therapy and in 263 of 2,877 (9.1%) patients who received endocrine therapy alone, with similar results between the two treatment groups (iDFS at 4 years: 84.2% v 84.5%; hazard ratio, 0.96; CI, 0.81 to 1.14; P = .65). No significant differences were observed for secondary time-to-event end points, and subgroup analyses did not show any differences by subgroup. There were no new safety signals for palbociclib in this trial. CONCLUSION: At this final analysis of the PALLAS trial, the addition of adjuvant palbociclib to standard endocrine therapy did not improve outcomes over endocrine therapy alone in patients with early hormone receptor-positive breast cancer.

Published
2022

14. Phase 1b trial of tagraxofusp in combination with azacitidine with or without venetoclax in acute myeloid leukemia

Author

Lane, Andrew A., Garcia, Jacqueline S., Raulston, Evangeline G., Garzon, Jada L., Galinsky, Ilene, Baxter, Emilie W., Leonard, Rebecca, DeAngelo, Daniel J., Luskin, Marlise R., Reilly, Christopher R., Stahl, Maximilian, Stone, Richard M., Vedula, Rahul S., Wadleigh, Martha M., Winer, Eric S., Mughal, Tariq, Brooks, Christopher, Gupta, Ira V., Stevenson, Kristen E., Neuberg, Donna S., Ren, Siyang, Keating, Julia, Konopleva, Marina, Stein, Anthony, and Pemmaraju, Naveen

Published
2024
Full Text
View/download PDF

15. Cutaneous Manifestations of Myeloid Neoplasms Exhibit Broad and Divergent Morphologic and Immunophenotypic Features but Share Ancestral Clonal Mutations With Bone Marrow

Author

Sadigh, Sam, DeAngelo, Daniel J., Garcia, Jacqueline S., Hasserjian, Robert P., Hergott, Christopher B., Lane, Andrew A., Lovitch, Scott B., Lucas, Fabienne, Luskin, Marlise R., Morgan, Elizabeth A., Pinkus, Geraldine S., Pozdnyakova, Olga, Rodig, Scott J., Shanmugam, Vignesh, Tsai, Harrison K., Winer, Eric S., Zemmour, David, and Kim, Annette S.

Published
2024
Full Text
View/download PDF

16. PD-L1 Immunohistochemistry Assay Comparison in Atezolizumab plus nab-Paclitaxel–Treated Advanced Triple-Negative Breast Cancer

Author

Rugo, Hope S, Loi, Sherene, Adams, Sylvia, Schmid, Peter, Schneeweiss, Andreas, Barrios, Carlos H, Iwata, Hiroji, Diéras, Véronique, Winer, Eric P, Kockx, Mark M, Peeters, Dieter, Chui, Stephen Y, Lin, Jennifer C, Duc, Anh Nguyen, Viale, Giuseppe, Molinero, Luciana, and Emens, Leisha A

Subjects
Cancer, Breast Cancer, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Humans, B7-H1 Antigen, Biomarkers, Tumor, Immunohistochemistry, Triple Negative Breast Neoplasms, Oncology and Carcinogenesis, Oncology & Carcinogenesis
Abstract

BackgroundIn the phase III IMpassion130 study, atezolizumab plus nab-paclitaxel (A+nP) showed clinical benefit in advanced or metastatic triple-negative breast cancer patients who were programmed death-ligand 1 (PD-L1)+ (tumor-infiltrating immune cells [IC] ≥1%) using the SP142 immunohistochemistry assay. Here we evaluate 2 other PD-L1 assays for analytical concordance with SP142 and patient-associated clinical outcomes.MethodsSamples from 614 patients (68.1% of intention-to-treat population) were centrally evaluated by immunohistochemistry for PD-L1 status on IC (VENTANA SP142, SP263, Dako 22C3) or as a combined positive score (CPS; 22C3).ResultsUsing SP142, SP263, and 22C3 assays, PD-L1 IC ≥1% prevalence was 46.4% (95% confidence interval [CI] = 42.5% to 50.4%), 74.9% (95% CI = 71.5% to 78.3%), and 73.1% (95% CI = 69.6% to 76.6%), respectively; 80.9% were 22C3 CPS ≥1. At IC ≥1% (+), the analytical concordance between SP142 and SP263 and 22C3 was 69.2% and 68.7%, respectively. Almost all SP142+ cases were captured by other assays (double positive), but several SP263+ (29.6%) or 22C3+ (29.0%) cases were SP142- (single positive). A+nP clinical activity vs placebo+nP in SP263+ and 22C3+ patients (progression-free survival [PFS] hazard ratios [HRs] = 0.64 to 0.68; overall survival [OS] HRs = 0.75 to 0.79) was driven by double-positive cases (PFS HRs = 0.60 to 0.61; OS HRs = 0.71 to 0.75) rather than single-positive cases (PFS HRs = 0.68 to 0.81; OS HRs = 0.87 to 0.95). Concordance for harmonized cutoffs for SP263 (IC ≥4%) and 22C3 (CPS ≥10) to SP142 (IC ≥1%) was subpar (approximately 75%).Conclusions22C3 and SP263 assays identified more patients as PD-L1+ (IC ≥1%) than SP142. No inter-assay analytical equivalency was observed. Consistent improved A+nP efficacy was captured by the SP142 PD-L1 IC ≥1% subgroup nested within 22C3 and SP263 PD-L1+ (IC ≥1%) populations.

Published
2021

17. The oral selective estrogen receptor degrader GDC-0810 (ARN-810) in postmenopausal women with hormone receptor-positive HER2-negative (HR + /HER2 −) advanced/metastatic breast cancer

Author

Bardia, Aditya, Mayer, Ingrid, Winer, Eric, Linden, Hannah M., Ma, Cynthia X., Parker, Barbara A., Bellet, Meritxell, Arteaga, Carlos L., Cheeti, Sravanthi, Gates, Mary, Chang, Ching-Wei, Fredrickson, Jill, Spoerke, Jill M., Moore, Heather M., Giltnane, Jennifer, Friedman, Lori S., Chow Maneval, Edna, Chan, Iris, and Jhaveri, Komal

Published
2023
Full Text
View/download PDF

19. Impact of pembrolizumab versus chemotherapy on health-related quality of life in patients with metastatic triple-negative breast cancer: results from the phase 3 randomised KEYNOTE-119 study

Author

Schmid, Peter, Lipatov, Oleg, Im, Seock-Ah, Goncalves, Anthony, Muñoz-Couselo, Eva, Lee, Keun Seok, Tamura, Kenji, Testa, Laura, Witzel, Isabell, Ohtani, Shoichiro, Turner, Nicholas, Zambelli, Stefania, Harbeck, Nadia, Andre, Fabrice, Dent, Rebecca, Mejia, Jaime A., Zhou, Xuan, Haiderali, Amin, Nguyen, Allison Martin, Cortes, Javier, and Winer, Eric P.

Published
2023
Full Text
View/download PDF

23. Anthracycline-containing and taxane-containing chemotherapy for early-stage operable breast cancer: a patient-level meta-analysis of 100 000 women from 86 randomised trials

Author

Braybrooke, Jeremy, Bradley, Rosie, Gray, Richard, Hills, Robert K, Pan, Hongchao, Peto, Richard, Dodwell, David, McGale, Paul, Taylor, Carolyn, Aihara, Tomohiko, Anderson, Stewart, Blum, Joanne, Cardoso, Fatima, Chen, Xiaosong, Crown, John P, Ejlertsen, Bent, Friedl, Thomas W P, Harbeck, Nadia, Janni, Wolfgang, Jensen, Maj-Britt, Mamounas, Eleftherios, Narui, Kazutaka, Nitz, Ulrike, Norton, Larry, O'Shaughnessy, Joyce, Piccart, Martine, Robert, Nicholas, Shao, Zhi-Ming, Slamon, Dennis, Sparano, Joseph, Watanabe, Toru, Yothers, Greg, Yu, Ke-Da, Berry, Richard, Boddington, Clare, Clarke, Mike, Davies, Christina, Davies, Lucy, Duane, Fran, Evans, Vaughan, Gay, Jo, Gettins, Lucy, Godwin, Jon, James, Sam, Lui, Hui, Lui, Zulian, MacKinnon, Elizabeth, Mannu, Gurdeep, McHugh, Theresa, Morris, Philip, Read, Simon, Straiton, Ewan, Buzdar, Aman, Suman, Vera J, Hunt, Kelly K, Leonard, Robert C F, Mansi, Janine, Delbaldo, Catherine, Piedbois, Pascal, Quinaux, Emmanuel, Fesl, Christian, Gnant, Michael, Sölkner, Lidija, Steger, Guenther, Eikesdal, Hans Petter, Lønning, Per Eystein, Bee, Valerie, Fung, Helena, Mackey, John, Martin, Miguel, Press, Michael, De Azambuja, Evandro, Gelber, Richard, Regan, Meredith, Di Leo, Angelo, Van Dooren, Veerle, Nogaret, Jean Marie, Bartlett, John, Chen, Bingshu E, Gelmon, Karen, Goss, Paul E, Levine, Mark N, Parulekar, Wendy, Pritchard, Kathleen I, Shepherd, Lois, Berry, Donald, Cirrincione, Constance, Shulman, Lawrence N, Winer, Eric, Gelman, Rebecca S, Harris, Jay R, Henderson, Craig, Shapiro, Charles L, Christiansen, Peer, Ewertz, Marianne, Mouridsen, Henning T, Van Leeuwen, Elise, Linn, Sabine, Van Rossum, Annelot G J, Van Tinteren, Harm, Van Werkhoven, Erik, Goldstein, Lori, Gray, Robert, Eiermann, Wolfgang, Gianni, Luca, Valagussa, Pinuccia, Bogaerts, Jan, Bonnefoi, Herve, Poncet, Coralie, Huovinen, Riikka, Joensuu, Heikki, Bonneterre, Jacques, Fargeot, Pierre, Fumoleau, Pierre, Kerbrat, Pierre, Luporsi, Elisabeth, Namer, Moïse, Carrasco, Eva M, Segui, Miguel Angel, Meisner, Christoph, Loibl, Sibylle, Nekljudova, Valentina, Thomssen, Christoph, Von Minckwitz, Gunter, Kümmel, Sherko, Lopez, Massimo, Vici, Patrizia, Fountzilas, George, Koliou, Georgia, Mavroudis, Dimitrios, Saloustros, Emmanouil, Brain, Etienne, Delaloge, Suzette, Michiels, Stefan, Mathoulin-Pelissier, Simone, Bines, Jose, Sarmento, Roberta M B, Bonadonna, Gianni, Brambilla, Cristina, Rossi, Anna, Bliss, Judith, Coombes, Raoul Charles, Kilburn, Lucy, Marty, Michel, Amadori, Dino, Boccardo, Francesco, Nanni, Oriana, Rubagotti, Alessandra, Scarpi, Emanuela, Masuda, Norikazu, Toi, Masakazu, Ueno, Takayuki, Ishikawa, Takashi, Matsumoto, Koji, Takao, Shintaro, Sommer, Harald, Foroglou, Pericles, Giokas, George, Kondylis, D, Lissaios, Byron, Reinisch, Mattea, Lee, Keun Seok, Nam, Byung-Ho, Ro, Jung Sil, De Matteis, Andrea, Perrone, Francesco, Tang, Gong, Wolmark, Norman, Hozumi, Yasuo, Nomura, Yasuo, Earl, Helena, Hiller, Louise, Vallier, Anne-Laure, De Mastro, Lucia, Venturini, Macro, Delozier, Thierry, Lemonnier, Jerome, Martin, Anne-Laure, Roché, Henri, Spielmann, Marc, Chen, Xiasong, Shen, Kunwei, Albain, Kathy, Barlow, William, Budd, George T, Gralow, Julie, Hayes, Dan, Bartlett-Lee, Peter, Ellis, Paul, Bianco, Angelo Raffaele, De Laurentiis, Michelino, De Placido, Sabino, Wildiers, Hans, Hsu, Limin, Eremin, Oleg, Walker, Leslie G, Ahlgren, Johan, Blomqvist, Carl, Holmberg, Lars, Lindman, Henrik, Asmar, Lina, Jones, Stephen E, Gluz, Oleg, Liedtke, Cornelia, Arriagada, Rodrigo, Bergsten-Nordström, Elizabeth, Carey, Lisa, Coleman, Robert, Cuzick, Jack, Davidson, Nancy, Dignam, James, Dowsett, Mitch, Francis, Prudence A, Goetz, Matthew P, Goodwin, Pam, Halpin-Murphy, Pat, Hill, Catherine, Jagsi, Reshma, Mukai, Hirofumi, Ohashi, Yasuo, Pierce, Lori, Poortmans, Philip, Raina, Vinod, Rea, Daniel, Robertson, John, Rutgers, Emiel, Salgado, Roberto, Spanic, Tanja, Tutt, Andrew, Viale, Giuseppe, Wang, Xiang, Whelan, Tim, Wilcken, Nicholas, Cameron, David, Bergh, Jonas, and Swain, Sandra M

Published
2023
Full Text
View/download PDF

24. Eprenetapopt combined with venetoclax and azacitidine in TP53-mutated acute myeloid leukaemia: a phase 1, dose-finding and expansion study

Author

Garcia-Manero, Guillermo, Goldberg, Aaron D, Winer, Eric S, Altman, Jessica K, Fathi, Amir T, Odenike, Olatoyosi, Roboz, Gail J, Sweet, Kendra, Miller, Crystal, Wennborg, Anders, Hickman, Denice K, Kanagal-Shamanna, Rashmi, Kantarjian, Hagop, Lancet, Jeffrey, Komrokji, Rami, Attar, Eyal C, and Sallman, David A

Published
2023
Full Text
View/download PDF

27. Second primary non-breast cancers in young breast cancer survivors

Author

Zhang, Bessie X., primary, Brantley, Kristen D., additional, Rosenberg, Shoshana M., additional, Kirkner, Gregory J., additional, Collins, Laura C., additional, Ruddy, Kathryn J., additional, Tamimi, Rulla M., additional, Schapira, Lidia, additional, Borges, Virginia F., additional, Warner, Ellen, additional, Come, Steven E., additional, Winer, Eric P., additional, Bellon, Jennifer R., additional, and Partridge, Ann H., additional

Published
2024
Full Text
View/download PDF

28. Predictive biomarkers of response to the IRAK4/FLT3 inhibitor emavusertib in hematological malignancies.

Author

Metzeler, Klaus H, primary, Platzbecker, Uwe, additional, Winer, Eric S., additional, Verma, Amit, additional, DeAngelo, Daniel J., additional, Severgnini, Mariano, additional, Choudhary, Gaurav S, additional, Zhao, Wanying, additional, Lane, Maureen E, additional, Gallagher, Cole, additional, Ferrari, Dora, additional, Masciarelli, Alyssa, additional, Von Roemeling, Reinhard W., additional, Carlisle, Samantha, additional, Nickle, David, additional, and Garcia-Manero, Guillermo, additional

Published
2024
Full Text
View/download PDF

29. Preliminary safety, efficacy and molecular characterization of emavusertib (CA-4948) in patients with relapsed/refractory (R/R) acute myeloid leukemia (AML) with FLT3 mutation (FLT3m).

Author

Winer, Eric S., primary, Verma, Amit, additional, Groepper, Stefanie, additional, Gotze, Katharina S., additional, Abaza, Yasmin, additional, Mikesch, Jan-Henrik, additional, Choudhary, Gaurav S, additional, Masciarelli, Alyssa, additional, Zhao, Wanying, additional, Gallagher, Cole, additional, Von Roemeling, Reinhard W., additional, and DeAngelo, Daniel J., additional

Published
2024
Full Text
View/download PDF

30. TBCRC 048 (olaparib expanded) expansion cohorts: Phase 2 study of olaparib monotherapy in patients (pts) with metastatic breast cancer (MBC) with germline (g) mutations in PALB2 or somatic (s) mutations in BRCA1 or BRCA2.

Author

Tung, Nadine M., primary, Robson, Mark E., additional, Nanda, Rita, additional, Li, Tianyu, additional, Vinayak, Shaveta, additional, Shah, Payal Deepak, additional, Khoury, Katia, additional, Kimmick, Gretchen Genevieve, additional, Santa-Maria, Cesar Augusto, additional, Brufsky, Adam, additional, DeMeo, Michelle, additional, Vieira, Joao Pedro, additional, Carey, Lisa A., additional, Wulf, Gerburg M., additional, Domchek, Susan M., additional, Krop, Ian E., additional, Wolff, Antonio C., additional, Winer, Eric P., additional, and Garber, Judy Ellen, additional

Published
2024
Full Text
View/download PDF

31. Outcomes with trastuzumab deruxtecan (T-DXd) by HER2 status and line of treatment in a large real-world database of patients with metastatic breast cancer.

Author

Tarantino, Paolo, primary, Lee, Do, additional, Foldi, Julia, additional, Soulos, Pamela R., additional, Gross, Cary Philip, additional, Grinda, Thomas, additional, Winer, Eric P., additional, Lin, Nancy U., additional, Krop, Ian E., additional, Tolaney, Sara M., additional, Lustberg, Maryam B., additional, and Sammons, Sarah L, additional

Published
2024
Full Text
View/download PDF

32. RNA-Seq based gene expression profiling of baseline and on-treatment breast tumors to predict response to HER2-directed therapy, without chemotherapy (TBCRC026).

Author

Hennessy, Maeve, primary, Fernández, Aranzazu, additional, Huang, Chiung Yu, additional, Cimino-Mathews, Ashley, additional, Denbow, Rita, additional, Abramson, Vandana G, additional, Rimawi, Mothaffar F., additional, Specht, Jennifer M., additional, Storniolo, Anna Maria, additional, Valero, Vicente, additional, Vaklavas, Chris, additional, Winer, Eric P., additional, Krop, Ian E., additional, Wolff, Antonio C., additional, Wahl, Richard L., additional, Thompson, E Aubrey, additional, Stearns, Vered, additional, Perou, Charles, additional, Carey, Lisa A., additional, and Connolly, Roisin M., additional

Published
2024
Full Text
View/download PDF

33. Prevalence and dynamics of circulating tumor DNA (ctDNA) among patients (pts) with HER2+ breast cancer (BC) receiving neoadjuvant paclitaxel/trastuzumab/pertuzumab (THP) in the DAPHNe trial.

Author

Waks, Adrienne Gropper, primary, Tarantino, Paolo, additional, Li, Tianyu, additional, Ogayo, Esther R., additional, Rahman, Tasnim, additional, DiLullo, Molly, additional, El-Refai, Sherif Mohamed, additional, Abbott, Charles, additional, Boyle, Sean Michael, additional, Chen, Richard, additional, Desai, Neelam Vijay, additional, Spring, Laura, additional, Tung, Nadine M., additional, King, Tari A., additional, Krop, Ian E., additional, Tayob, Nabihah, additional, Mittendorf, Elizabeth A., additional, Tolaney, Sara M., additional, Winer, Eric P., additional, and Parsons, Heather Anne, additional

Published
2024
Full Text
View/download PDF

34. Clinicogenomic characterization of inflammatory breast cancer

Author

Priedigkeit, Nolan, primary, Harrison, Beth, additional, Shue, Robert, additional, Hughes, Melissa E., additional, Li, Yvonne, additional, Kirkner, Gregory J., additional, Spurr, Liam F., additional, Remolano, Marie Claire, additional, Strauss, Sarah, additional, Files, Janet, additional, Feeney, Anne-Marie, additional, Grant, Libby, additional, Mohammed-Abreu, Ayesha, additional, Garrido-Castro, Ana, additional, Sousa, Romualdo Barroso, additional, Bychkovsky, Brittany, additional, Nakhlis, Faina, additional, Bellon, Jennifer R., additional, King, Tari A., additional, Winer, Eric P., additional, Lindeman, Neal, additional, Johnson, Bruce E., additional, Sholl, Lynette, additional, Dillon, Deborah, additional, Overmoyer, Beth, additional, Tolaney, Sara M., additional, Cherniack, Andrew, additional, Lin, Nancy U., additional, and Lynce, Filipa, additional

Published
2024
Full Text
View/download PDF

35. Aspirin vs Placebo as Adjuvant Therapy for Breast Cancer

Author

Chen, Wendy Y., primary, Ballman, Karla V., additional, Partridge, Ann H., additional, Hahn, Olwen M., additional, Briccetti, Frederick M., additional, Irvin, William J., additional, Symington, Banu, additional, Visvanathan, Kala, additional, Pohlmann, Paula R., additional, Openshaw, Thomas H., additional, Weiss, Anna, additional, Winer, Eric P., additional, Carey, Lisa A., additional, and Holmes, Michelle D., additional

Published
2024
Full Text
View/download PDF

36. Contribution of tumour and immune cells to PD‐L1 expression as a predictive biomarker in metastatic triple‐negative breast cancer: exploratory analysis from KEYNOTE‐119

Author

Cortes, Javier, primary, Winer, Eric P, additional, Lipatov, Oleg, additional, Im, Seock‐Ah, additional, Gonçalves, Anthony, additional, Muñoz‐Couselo, Eva, additional, Lee, Keun Seok, additional, Schmid, Peter, additional, Tamura, Kenji, additional, Testa, Laura, additional, Witzel, Isabell, additional, Ohtani, Shoichiro, additional, Hund, Stephanie, additional, Kulangara, Karina, additional, Karantza, Vassiliki, additional, Mejia, Jaime A, additional, Ma, Junshui, additional, Jelinic, Petar, additional, Huang, Lingkang, additional, Pruitt, Scott K, additional, and Emancipator, Kenneth, additional

Published
2024
Full Text
View/download PDF

37. Second Primary Breast Cancer in Young Breast Cancer Survivors

Author

Brantley, Kristen D., primary, Rosenberg, Shoshana M., additional, Collins, Laura C., additional, Ruddy, Kathryn J., additional, Tamimi, Rulla M., additional, Schapira, Lidia, additional, Borges, Virginia F., additional, Warner, Ellen, additional, Come, Steven E., additional, Zheng, Yue, additional, Kirkner, Gregory J., additional, Snow, Craig, additional, Winer, Eric P., additional, and Partridge, Ann H., additional

Published
2024
Full Text
View/download PDF

40. Local Therapy Outcomes and Toxicity From the ATEMPT Trial (TBCRC 033): A Phase II Randomized Trial of Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab in Women With Stage I HER2-Positive Breast Cancer

Author

Bellon, Jennifer R., Tayob, Nabihah, Yang, David D., Tralins, Jordan, Dang, Chau T., Isakoff, Steven J., DeMeo, Michelle, Burstein, Harold J., Partridge, Ann H., Winer, Eric P., Krop, Ian E., and Tolaney, Sara M.

Published
2022
Full Text
View/download PDF

41. Temporal and spatial topography of cell proliferation in cancer

Author

Gaglia, Giorgio, Kabraji, Sheheryar, Rammos, Danae, Dai, Yang, Verma, Ana, Wang, Shu, Mills, Caitlin E., Chung, Mirra, Bergholz, Johann S., Coy, Shannon, Lin, Jia-Ren, Jeselsohn, Rinath, Metzger, Otto, Winer, Eric P., Dillon, Deborah A., Zhao, Jean J., Sorger, Peter K., and Santagata, Sandro

Published
2022
Full Text
View/download PDF

46. A prospective trial of treatment de-escalation following neoadjuvant paclitaxel/trastuzumab/pertuzumab in HER2-positive breast cancer

Author

Waks, Adrienne G., Desai, Neelam V., Li, Tianyu, Poorvu, Philip D., Partridge, Ann H., Sinclair, Natalie, Spring, Laura M., Faggen, Meredith, Constantine, Michael, Metzger, Otto, Alberti, Jillian, Deane, Julia, Rosenberg, Shoshana M., Frank, Elizabeth, Tolaney, Sara M., Krop, Ian E., Tung, Nadine M., Tayob, Nabihah, King, Tari A., Mittendorf, Elizabeth A., and Winer, Eric P.

Published
2022
Full Text
View/download PDF

47. Cardiac outcomes of subjects on adjuvant trastuzumab emtansine vs paclitaxel in combination with trastuzumab for stage I HER2-positive breast cancer (ATEMPT) study (TBCRC033): a randomized controlled trial

Author

Barroso-Sousa, Romualdo, Tarantino, Paolo, Tayob, Nabihah, Dang, Chau, Yardley, Denise A., Isakoff, Steven J., Valero, Vicente, Faggen, Meredith, Mulvey, Therese, Bose, Ron, Hu, Jiani, Weckstein, Douglas, Wolff, Antonio C., Reeder-Hayes, Katherine, Rugo, Hope S., Ramaswamy, Bhuvaneswari, Zuckerman, Dan, Hart, Lowell, Gadi, Vijayakrishna K., Constantine, Michael, Cheng, Kit, Briccetti, Frederick, Schneider, Bryan, Garrett, Audrey Merrill, Marcom, Kelly, Albain, Kathy, DeFusco, Patricia, Tung, Nadine, Ardman, Blair, Nanda, Rita, Jankowitz, Rachel C., Rimawi, Mothaffar, Abramson, Vandana, Pohlmann, Paula R., Van Poznak, Catherine, Forero-Torres, Andres, Liu, Minetta, Ruddy, Kathryn J., Zheng, Yue, Rosenberg, Shoshana M., Gelber, Richard D., Trippa, Lorenzo, Barry, William, DeMeo, Michelle, Burstein, Harold, Partridge, Ann, Winer, Eric P., Krop, Ian, and Tolaney, Sara M.

Published
2022
Full Text
View/download PDF

48. STING agonism reprograms tumor-associated macrophages and overcomes resistance to PARP inhibition in BRCA1-deficient models of breast cancer

Author

Wang, Qiwei, Bergholz, Johann S., Ding, Liya, Lin, Ziying, Kabraji, Sheheryar K., Hughes, Melissa E., He, Xiadi, Xie, Shaozhen, Jiang, Tao, Wang, Weihua, Zoeller, Jason J., Kim, Hye-Jung, Roberts, Thomas M., Konstantinopoulos, Panagiotis A., Matulonis, Ursula A., Dillon, Deborah A., Winer, Eric P., Lin, Nancy U., and Zhao, Jean J.

Published
2022
Full Text
View/download PDF

50. Transcriptional differences between JAK2-V617F and wild-type bone marrow cells in patients with myeloproliferative neoplasms

Author

Van Egeren, Debra, Kamaz, Baransel, Liu, Shichen, Nguyen, Maximilian, Reilly, Christopher R., Kalyva, Maria, DeAngelo, Daniel J., Galinsky, Ilene, Wadleigh, Martha, Winer, Eric S., Luskin, Marlise R., Stone, Richard M., Garcia, Jacqueline S., Hobbs, Gabriela S., Michor, Franziska, Cortes-Ciriano, Isidro, Mullally, Ann, and Hormoz, Sahand

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results